Shares of NeoGenomics NEO were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share fell 14.29% year over year to $0.06, which beat the estimate of $0.04.
Revenue of $125,444,000 higher by 19.84% year over year, which missed the estimate of $126,230,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
NeoGenomics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Oct 27, 2020
Time: 08:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1219/37902
Technicals
52-week high: $44.58
Company's 52-week low was at $19.67
Price action over last quarter: Up 11.78%
Company Description
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.